ArticleJournal of substance abuse treatment2018
Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Article in Journal of substance abuse treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
146 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence.Drug and alcohol dependence · 2021Pooled it
- Pooled it
- Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.Epidemiologic reviews · 2020Pooled it
- Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I feasibility, usability and efficacy pilot randomized clinical trial.Drug and alcohol dependence · 2024Trial
- Design of CLARO+ (Collaboration Leading to Addiction Treatment and Recovery from Other Stresses, Plus): A randomized trial of collaborative care to decrease overdose and suicide risk among patients with co-occurring disorders.Contemporary clinical trials · 2023Trial
- Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: Multistate Retrospective Cohort Study.Journal of medical Internet research · 2026Article
- Trait impulsivity prospectively predicts lower methadone treatment retention: moderation by pain catastrophizing.Addiction science & clinical practice · 2026Observational
- Safety of Additional Local Anesthetics Soon After Liposomal Bupivacaine: A Retrospective Cohort Study.Cureus · 2026Article
- Medicaid Prior Authorization and Discontinuation of Buprenorphine.Journal of addiction medicine · 2026Article
- Exploratory associations between co-occurring opioid and alcohol use disorders and GIP/GLP-1 receptor agonist treatment.Communications medicine · 2026Article
- Trajectories of Medication Utilization for Opioid Use Disorder in Pregnancy and Associated Maternal Outcomes.O&G open · 2026Article
- Association of Emergency Department Buprenorphine Initiation With Subsequent Pharmacotherapy and Outcomes Among Patients With Opioid Use Disorder.Journal of addiction medicine · 2026Article
- Mediation of chronic pain and disability on opioid use disorder risk by pain management practices among adult Medicaid patients, 2016-2019.American journal of epidemiology · 2026Article
- Differences in buprenorphine initiation and retention for opioid use disorder between primary care and substance use disorder specialty care settings.Journal of substance use and addiction treatment · 2026Article
- Evaluating the optimal duration of medication treatment for opioid use disorder.Addiction (Abingdon, England) · 2026Article
- IFN-γ and TLR agonist co-adjuvants enhance the efficacy of a lipid-PLGA hybrid nanoparticle-based oxycodone vaccine.Biomaterials · 2026Article
- Demoralization, employment status, and early symptom reduction as correlates of treatment discontinuation in outpatient alcohol use disorder.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Article
- Recanting Twins: Addressing Intermediate Confounding in Mediation Analysis.Statistics in medicine · 2026Article
- Retention on Buprenorphine for Opioid Use Disorder in Justice-Involved Individuals: A Retrospective Cohort Study.Behavioral sciences (Basel, Switzerland) · 2026Article
- Timely Receipt of New Medication Treatment After Acute Care Encounters for Opioid Overdose in the U.S. Medicaid Population.Journal of general internal medicine · 2026Article
86 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionRecent U.S. trends demonstrate sharp rises in adverse opioid-related health outcomes, including opioid use disorder (OUD), overdose, and death. Yet few affected people receive treatment for OUD and a minority of those who receive treatment are effectively retained in care. The purpose of this study was to examine duration of buprenorphine treatment for OUD following treatment initiation to identify risk factors for early discontinuation.
methodsWe analyzed insurance claims from the 2013-2015 MarketScan multi-state Medicaid database. The sample included adults 18-64 years old with an OUD diagnosis in the 6 months before initiating buprenorphine treatment, defined as 6 months without a buprenorphine claim prior to the index buprenorphine claim (N = 17,329 individuals). We used Cox proportional hazards regression to estimate risk of discontinuing treatment (>30 days without buprenorphine supply), and logistic regression to estimate the odds of persistent treatment for a minimum of 180 days.
resultsOver one-quarter of the sample discontinued buprenorphine in the first month of treatment (N = 4928; 28.4%) and most discontinued before 180 days (N = 11,189; 64.6%). In the proportional hazards model, risk factors for discontinuation included a lower initial buprenorphine dose (≤4 mg; Hazard Ratio [HR] = 1.72, p < .001), male sex (HR = 1.19, p < .001), younger age (HR = 1.34, p < .001), minority race/ethnicity (black HR = 1.31, p < .001; Hispanic HR = 1.24, p = .01; other HR = 1.09, p < .001), capitated insurance (HR = 1.21, p < .001), comorbid substance use disorders (alcohol HR = 1.07, p = .04; non-opioid drugs HR = 1.14, p < .001), hepatitis C (HR = 1.06, p = .01), opioid overdose history (HR = 1.20, p = .001), or any inpatient care (HR = 1.22, p < .001) in the 6-month baseline period. In logistic models, these risk factors were similarly associated with significantly lower odds of treatment retention for at least 180 days.
conclusionFor Medicaid beneficiaries with OUD treated with buprenorphine, there is a need to implement treatment models that more effectively address barriers to treatment retention. These barriers are particularly challenging for minorities, younger individuals, and those with additional substance use disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.